Page last updated: 2024-09-05

enzastaurin and Lymphoma, T-Cell, Cutaneous

enzastaurin has been researched along with Lymphoma, T-Cell, Cutaneous in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Krett, NL; Rosen, ST; Rovedo, MA	1
Bian, Y; Boye, M; Day, JM; Duvic, M; Hamid, O; Kim, YH; Kuzel, TM; Lin, B; Mark, LA; Musiek, A; Pinter-Brown, L; Porcu, P; Querfeld, C; Rook, AH; Rosen, ST	1
Guitart, J; Krett, NL; Kuzel, TM; Querfeld, C; Rademaker, A; Rizvi, MA; Rosen, ST; Sabharwal, SS	1

Trials

1 trial(s) available for enzastaurin and Lymphoma, T-Cell, Cutaneous

Article	Year
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia & lymphoma, 2011, Volume: 52, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hyperkalemia; Indoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Recurrence; Sezary Syndrome; Skin Neoplasms; Treatment Outcome	2011

Article

Year

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.

Leukemia & lymphoma, 2011, Volume: 52, Issue:8

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hyperkalemia; Indoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Recurrence; Sezary Syndrome; Skin Neoplasms; Treatment Outcome

2011

Other Studies

2 other study(ies) available for enzastaurin and Lymphoma, T-Cell, Cutaneous

Article	Year
Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. The Journal of investigative dermatology, 2011, Volume: 131, Issue:7 Topics: Antineoplastic Agents; beta Catenin; Cells, Cultured; Glycogen Synthase Kinase 3; Humans; Hyaluronan Receptors; Indoles; Lymphoma, T-Cell, Cutaneous; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; TCF Transcription Factors; Thiazoles; Urea	2011
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. The Journal of investigative dermatology, 2006, Volume: 126, Issue:7 Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Lymphoma, T-Cell, Cutaneous; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6; Signal Transduction; Skin Neoplasms	2006

Article

Year

Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.

The Journal of investigative dermatology, 2011, Volume: 131, Issue:7

Topics: Antineoplastic Agents; beta Catenin; Cells, Cultured; Glycogen Synthase Kinase 3; Humans; Hyaluronan Receptors; Indoles; Lymphoma, T-Cell, Cutaneous; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; TCF Transcription Factors; Thiazoles; Urea

2011

The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.

The Journal of investigative dermatology, 2006, Volume: 126, Issue:7

Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Lymphoma, T-Cell, Cutaneous; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6; Signal Transduction; Skin Neoplasms

2006